Cargando…

Molecular Docking Studies with Rabies Virus Glycoprotein to Design Viral Therapeutics

The genome of rabies virus encodes five proteins; the nucleoprotein, the phosphoprotein, the matrix protein, the glycoprotein, and the RNA-dependent RNA polymerase. Among these, the glycoprotein is the most important as it is the major contributor to pathogenicity and virus neutralizing antibody res...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomar, N. R., Singh, V., Marla, S. S., Chandra, R., Kumar, R., Kumar, A.
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3013581/
https://www.ncbi.nlm.nih.gov/pubmed/21218060
http://dx.doi.org/10.4103/0250-474X.73905
_version_ 1782195287013457920
author Tomar, N. R.
Singh, V.
Marla, S. S.
Chandra, R.
Kumar, R.
Kumar, A.
author_facet Tomar, N. R.
Singh, V.
Marla, S. S.
Chandra, R.
Kumar, R.
Kumar, A.
author_sort Tomar, N. R.
collection PubMed
description The genome of rabies virus encodes five proteins; the nucleoprotein, the phosphoprotein, the matrix protein, the glycoprotein, and the RNA-dependent RNA polymerase. Among these, the glycoprotein is the most important as it is the major contributor to pathogenicity and virus neutralizing antibody response. Keeping in mind that glycoprotein is the only protein exposed on the surface of virus and is thought to be responsible for the interaction with the cell membrane, it was attempted to target glycoprotein by a ligand polyethylene glycol 4000, which blocks its active site, as seen by molecular operating environment software, so that it may be possible to prevent the spread of virus into the host. The ligand polyethylene glycol 4000 was retrieved from Research Collaboratory for Structural Bioinformatics protein data bank by providing the glycoprotein sequence to the databank. In this study it was observed that the ligand was successfully docked on a major portion of antigenic site II of glycoprotein by mimicking the virus neutralizing antibodies. This knowledge may be important for the development of novel therapies for the treatment of rabies and other viral diseases in the future.
format Text
id pubmed-3013581
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-30135812011-01-07 Molecular Docking Studies with Rabies Virus Glycoprotein to Design Viral Therapeutics Tomar, N. R. Singh, V. Marla, S. S. Chandra, R. Kumar, R. Kumar, A. Indian J Pharm Sci Research Papers The genome of rabies virus encodes five proteins; the nucleoprotein, the phosphoprotein, the matrix protein, the glycoprotein, and the RNA-dependent RNA polymerase. Among these, the glycoprotein is the most important as it is the major contributor to pathogenicity and virus neutralizing antibody response. Keeping in mind that glycoprotein is the only protein exposed on the surface of virus and is thought to be responsible for the interaction with the cell membrane, it was attempted to target glycoprotein by a ligand polyethylene glycol 4000, which blocks its active site, as seen by molecular operating environment software, so that it may be possible to prevent the spread of virus into the host. The ligand polyethylene glycol 4000 was retrieved from Research Collaboratory for Structural Bioinformatics protein data bank by providing the glycoprotein sequence to the databank. In this study it was observed that the ligand was successfully docked on a major portion of antigenic site II of glycoprotein by mimicking the virus neutralizing antibodies. This knowledge may be important for the development of novel therapies for the treatment of rabies and other viral diseases in the future. Medknow Publications 2010 /pmc/articles/PMC3013581/ /pubmed/21218060 http://dx.doi.org/10.4103/0250-474X.73905 Text en © Indian Journal of Pharmaceutical Sciences http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Papers
Tomar, N. R.
Singh, V.
Marla, S. S.
Chandra, R.
Kumar, R.
Kumar, A.
Molecular Docking Studies with Rabies Virus Glycoprotein to Design Viral Therapeutics
title Molecular Docking Studies with Rabies Virus Glycoprotein to Design Viral Therapeutics
title_full Molecular Docking Studies with Rabies Virus Glycoprotein to Design Viral Therapeutics
title_fullStr Molecular Docking Studies with Rabies Virus Glycoprotein to Design Viral Therapeutics
title_full_unstemmed Molecular Docking Studies with Rabies Virus Glycoprotein to Design Viral Therapeutics
title_short Molecular Docking Studies with Rabies Virus Glycoprotein to Design Viral Therapeutics
title_sort molecular docking studies with rabies virus glycoprotein to design viral therapeutics
topic Research Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3013581/
https://www.ncbi.nlm.nih.gov/pubmed/21218060
http://dx.doi.org/10.4103/0250-474X.73905
work_keys_str_mv AT tomarnr moleculardockingstudieswithrabiesvirusglycoproteintodesignviraltherapeutics
AT singhv moleculardockingstudieswithrabiesvirusglycoproteintodesignviraltherapeutics
AT marlass moleculardockingstudieswithrabiesvirusglycoproteintodesignviraltherapeutics
AT chandrar moleculardockingstudieswithrabiesvirusglycoproteintodesignviraltherapeutics
AT kumarr moleculardockingstudieswithrabiesvirusglycoproteintodesignviraltherapeutics
AT kumara moleculardockingstudieswithrabiesvirusglycoproteintodesignviraltherapeutics